Characteristics of Chemotherapy Treatments for Breast Cancer Patients at Bhayangkara Tk.1 Pudsdokkes Polri Hospital, Jakarta

Amelia Febriani, Fitria Pujiastuti, Teodhora Teodhora

Abstract


Background: Breast cancer is a malignant breast tumor that develops in the ductal or lobular epithelium and usually attacks women. Chemotherapy is a cornerstone of breast cancer treatment, particularly for patients with advanced disease or those who are not candidates for surgery or radiation therapy. This research aims to observe the use of chemotherapy drugs for breast cancer patients in terms of chemotherapy regimens and cycles at Bhayangkara Tk.1 Pudsdokkes Polri  Hospital.

 

Methods: This study employs descriptive quantitative approaches. Data were gathered retrospectively from medical records of breast cancer patients receiving chemotherapy at Bhayangkara Tk.1 Pudsdokkes Polri  Hospital Jakarta from July to December 2021.

 

Results: From 110 patients, 86 (78.18%) patients used the CAF regimen, 18 (16.36%) patients used the AC regimen, and 3 (2.73%) patients used the TAC regimen, while the regimen that did not comply with the guidelines was 2 (1.82%) patients using the combination of paclitaxel and epirubicin, 1 patient utilizing the combination of paclitaxel and doxorubicin. Forty-six (41.82%) patients with the CAF regimen had completed six cycles of chemotherapy with intervals of 3 weeks or 21 days, while only 5 patients (3.63%) completed four cycles of the AC regimen at 3-week or 21-day intervals. At the time of data collection, 11 patients, and 1 patient utilizing the AC regimen. This was because 59 patients had not yet finished the chemotherapy cycle, specifically in the advanced stage.

 

Conclusions: The CAF regimen was the most commonly used chemotherapy regimen, followed by the AC and TAC regimens. This finding aligns with current clinical guidelines for breast cancer treatment. A significant number of patients had not yet completed their chemotherapy cycles, particularly those with advanced-stage breast cancer. This highlights the challenges associated with treating advanced disease and the need for more effective and less toxic treatment options.


Keywords


breast cancer, chemotherapy, regimens

Full Text: View | Download

DOI: 10.33371/ijoc.v18i3.1131

Article Metrics

Abstract View: 147,
PDF Download: 75
             

References


World Health Organization. Breast Cancer [Internet]. 2021 [cited 2023 Jan 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.

Kementerian Kesehatan RI. Panduan Penatalaksanaan Kanker Payudara. Jakarta: Departemen Kesehatan RI; 2018.

American Cancer Society. How Chemotherapy Drugs Work [Internet]. Atlanta: American Cancer Society, Inc.; 2022 [cited 2023 Jan 1]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.html.

McDonald ES, Clark AS, Tchou J, ET AL. Clinical Diagnosis and Management of Breast Cancer. J Nucl Med. 2016;57(Suppl 1):9S-16S.

Cancer Council Australia. Chemotherapy Understanding Booklet [Internet]. 2018 [cited 2023 Jan 1]. Available from: https://www.cancer.org.au/assets/pdf/understanding-chemotherapy-booklet.

Irawati I, Sardjan M. Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. Pharmademica J Kefarmasian Gizi. 2022;1(2):80-5.

Łukasiewicz S, Czeczelewski M, Forma A, Baj J, ET AL. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers. 2021;13(17):4287.

Terkola R, Bardin C, Lizeaga Cundin G, ET AL. Identifying options for oncology therapy regimen codification to improve standardization—combined results of an expert panel and a review. J Clin Pharm Ther. 2021;46(5):1238-44.

Caudell JJ, Gillison ML, Maghami E, et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2022;20(3):224-34.

Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106.

Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97.

Arisanti JP, Saptarina N, Andarini YD. Evaluasi penggunaan obat kemoterapi pada penderita kanker payudara di RSUP dr. Seoradji Tirtonegoro periode 2018. Pharmasipha. 2020;4(2):1-8.

Fajar IM, Heriady Y, Aji HW. Karakteristik usia, gambaran klinis dan histopatologi pasien kanker payudara di RSUD Al-Ihsan Provinsi Jawa Barat periode Januari 2018-Oktober 2020. J Riset Kedokteran. 2021;85-91.

Kolak A, Kamińska M, Sygit K, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med. 2017;24(4).

Nuraini N, Megawati S, Wahyuningtyas D. Evaluasi penggunaan obat kemoterapi pada pasien kanker payudara di Rumah Sakit Umum Kabupaten Tangerang. J Farmagazine. 2022;9(2):34-9.

Rowawi R. Hubungan siklus kemoterapi dengan tingkat kecemasan pada penderita kanker payudara di RSUD Al Ihsan Provinsi Jawa Barat. J Sehat Masada. 2017;11(2):219-31.

Utami SS, Mustikasari M. Aspek psikososial pada penderita kanker payudara: studi pendahuluan. J Keperawatan Indones. 2017;20(2):65-74.

Harvie M, Howell A, Arden-Close E, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2022;126(8):1157-67.

Setyaningsih TRP, Wahyurianto Y, Yasin MF. Tingkat depresi pasien kanker payudara. J Keperawatan. 2013;6(3):1979-8091.

Marwin M, Perwitasari DA, Purba FD, ET AL. Hubungan karakteristik terhadap kualitas hidup pasien kanker payudara yang menjalani kemoterapi di RSUP Dr. Kariadi Semarang. J Sains Kesehatan. 2021;3(3):505-12.

Narisuari ID, Manuaba IB. Prevalensi dan gambaran karakteristik penderita kanker payudara di poliklinik bedah onkologi RSUP Sanglah, Bali, Indonesia tahun 2016. Intisari Sains Medis. 2020;11(1):183-9.

Desweni E, Harahap WA, Afriwardi A. Pemeriksaan payudara sendiri (SADARI) dengan stadium kanker payudara. J Telenurs. 2021;3(2):629-35.

Brown LC, Murphy C, Gibson F, et al. Posttraumatic stress disorder and breast cancer: risk factors and the role of inflammation and endocrine function. Cancer. 2020;126(14):3181-91.

Graells-Sans A, Serral G, Puigpinós-Riera R, ET AL. Social inequalities in quality of life in a cohort of women diagnosed with breast cancer in Barcelona. Cancer Epidemiol. 2018;54:38-47.

Sulistyowati I, Utami LR, Jamil M. Deteksi dini kanker payudara dengan SADARI dan SADANIS. J Implementasi Pengabdian Masyarakat Kesehatan. 2022;4(1).

Sukandar EY, Hartini S, Rizkita P. Evaluasi reaksi obat merugikan pada pasien kemoterapi kanker payudara di salah satu rumah sakit di Bandung. J Ilmu Kefarmasian Indones. 2014;12(2):183-92.

Amjad MT, Chidharla A, Kasi A. Kemoterapi kanker [Internet]. Treasure Island (FL): StatPearls; 2022 [cited 2023 Jan 1]. Available from:

https://www.ncbi.nlm.nih.gov/books/NBK564367/.

Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019;(2).

Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol. 2022;13:750507.

Minella C, Boggia S, Gulla A, et al. Surgery after neoadjuvant chemotherapy: a clip-based technique to improve surgical outcomes. Cancers. 2022;14(9):2229.

Werida RH, Elshafiey RA, Ghoneim A, et al. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. Support Care Cancer. 2022;30(9):7281-92.

Lück HJ, Du Bois A, Loibl S, et al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat. 2013;139(3):779-87.

Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-95.

Indah F, Qodir N. Faktor-faktor yang mempengaruhi ketepatan siklus kemoterapi pada pasien kanker payudara. J Kep Indones. 2018;21(3).

Juwita DA, Almahdy A, Afdhila R. Pengaruh karakteristik pasien terhadap kualitas hidup terkait kesehatan pada pasien kanker payudara di RSUP Dr. M. Djamil Padang, Indonesia. J Sains Farm Klin. 2018;5(2):126-33.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.